Pemetrexed-induced edema of the eyelid.
Pemetrexed is a novel antimetabolite that targets multiple enzymes in the folate pathway, and has exhibited clear antitumor activities in the treatment of malignant pleural mesothelioma and non-small cell lung cancer. Although many adverse events of pemetrexed, such as bone marrow suppression, have been reported, edema of the eyelid has been previously reported in only one case (0.2%, n=519), according to the Pemetrexed Clinical Investigator's Brochure, April 2005 version. We experienced a patient who developed the valuable edema of the eyelid. We believe that medical oncologists should be aware of this rare adverse event, although the mechanism responsible for it is not yet known.
Kurata
Takayasu
T
Department of Medical Oncology, Kinki University School of Medicine, 377-2 Ohno-Higashi Osaka-Sayama, Osaka 589-8511, Japan. ctc002@poh.osaka-med.ac.jp
Tamura
Kenji
K
Okamoto
Isamu
I
Satoh
Taroh
T
Nakagawa
Kazuhiko
K
Fukuoka
Masahiro
M
D000230:Adenocarcinoma / Q000188:drug therapy; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D003907:Dexamethasone / Q000627:therapeutic use; D004487:Edema / Q000139:chemically induced* / Q000188:drug therapy; D005141:Eyelid Diseases / Q000139:chemically induced*; D005143:Eyelids / Q000187:drug effects* / Q000473:pathology; D005971:Glutamates / Q000009:adverse effects* / Q000627:therapeutic use; D006147:Guanine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D000068437:Pemetrexed
D000964:Antimetabolites, Antineoplastic; D005971:Glutamates; D000068437:Pemetrexed; D006147:Guanine; D003907:Dexamethasone